Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 8/20 for events on 8/19 - check for details.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting other events and financial statements as of August 19, 2025. The filing does not detail specific events or financial figures but serves as a notification of these items.
Why It Matters
This filing indicates that Axsome Therapeutics has reported significant events and financial updates, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain specific negative or positive news that would immediately alter risk.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
- August 20, 2025 (date) — Date of Report
FAQ
What specific 'Other Events' are being reported by Axsome Therapeutics?
The provided text does not specify the 'Other Events' being reported; it only indicates that this item is included in the 8-K filing.
What is the significance of filing 'Financial Statements and Exhibits' on an 8-K?
Filing financial statements and exhibits on an 8-K typically accompanies significant corporate events or provides updated financial information that is material to investors.
What is the exact date of the report for this 8-K filing?
The report date is August 20, 2025.
What is the earliest event date reported in this filing?
The earliest event reported is August 19, 2025.
What is Axsome Therapeutics' state of incorporation and IRS Employer Identification Number?
Axsome Therapeutics, Inc. is incorporated in Delaware and has an IRS Employer Identification Number of 45-4241907.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-20 17:01:38
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20250819.htm (8-K) — 45KB
- 0001579428-25-000007.txt ( ) — 144KB
- axsm-20250819.xsd (EX-101.SCH) — 23KB
- axsm-20250819_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 19, 2025, Axsome Therapeutics, Inc. (the "Company") received a Paragraph IV Certification Notice Letter (the "Notice Letter") from Apotex Inc. ("Apotex"), providing notification to the Company that Apotex has submitted an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") seeking approval to manufacture, use, or sell a generic version of Symbravo (meloxicam-rizatriptan benzoate). The Company anticipates responding to the Notice Letter in due course.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: August 20, 2025 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer